# Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

> **NCT00754494** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Adenomatous Polyp
- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage I Colon Cancer
- Stage I Rectal Cancer
- Stage IIA Colon Cancer
- Stage IIA Rectal Cancer
- Stage IIB Colon Cancer
- Stage IIB Rectal Cancer
- Stage IIC Colon Cancer
- Stage IIC Rectal Cancer
- Stage IIIA Colon Cancer
- Stage IIIA Rectal Cancer
- Stage IIIB Colon Cancer
- Stage IIIB Rectal Cancer
- Stage IIIC Colon Cancer
- Stage IIIC Rectal Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00754494
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-10
- **Final completion:** 2013-09
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00754494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00754494, "Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00754494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*